What is HC Wainwright’s Estimate for PMVP FY2026 Earnings?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for PMV Pharmaceuticals in a report released on Friday, September 19th. HC Wainwright analyst R. Burns expects that the company will earn ($1.63) per share for the year. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.06) per share.

PMV Pharmaceuticals Stock Up 3.0%

PMVP stock opened at $1.38 on Monday. PMV Pharmaceuticals has a twelve month low of $0.81 and a twelve month high of $1.84. The stock’s 50 day moving average is $1.41 and its 200-day moving average is $1.17. The firm has a market capitalization of $73.13 million, a PE ratio of -0.88 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its earnings results on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

Insider Activity

In related news, major shareholder Orbimed Advisors Llc sold 500,000 shares of PMV Pharmaceuticals stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $1.80, for a total transaction of $900,000.00. Following the sale, the insider directly owned 5,975,291 shares in the company, valued at approximately $10,755,523.80. This trade represents a 7.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David Henry Mack sold 58,411 shares of PMV Pharmaceuticals stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $61,915.66. Following the sale, the chief executive officer owned 536,133 shares in the company, valued at $568,300.98. This trade represents a 9.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 614,627 shares of company stock worth $1,021,505 over the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of PMV Pharmaceuticals

Large investors have recently bought and sold shares of the company. Shay Capital LLC purchased a new position in shares of PMV Pharmaceuticals in the second quarter valued at $26,000. Stonepine Capital Management LLC grew its position in PMV Pharmaceuticals by 34.2% during the second quarter. Stonepine Capital Management LLC now owns 845,968 shares of the company’s stock worth $897,000 after buying an additional 215,785 shares in the last quarter. BML Capital Management LLC grew its position in PMV Pharmaceuticals by 33.4% during the second quarter. BML Capital Management LLC now owns 5,000,000 shares of the company’s stock worth $5,300,000 after buying an additional 1,252,388 shares in the last quarter. Acadian Asset Management LLC grew its position in PMV Pharmaceuticals by 0.9% during the second quarter. Acadian Asset Management LLC now owns 2,066,137 shares of the company’s stock worth $2,188,000 after buying an additional 18,960 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in PMV Pharmaceuticals by 128.7% during the second quarter. Assenagon Asset Management S.A. now owns 263,059 shares of the company’s stock worth $279,000 after buying an additional 148,021 shares in the last quarter. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.